SCHEMBL13878751

SCHEMBL13878751

Cc1cn(-c2cc(C(=O)Nc3ccc(C)c(NC(=O)c4cnc(Nc5cc(NCCO)nc(C)n5)s4)c3)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.57
KDM4E B2RXH2 1/20 0.53
POLB P06746 1/20 0.53
RECQL P46063 1/20 0.53
MAPT P10636 1/20 0.52
ABL1 P00519 8/20 0.51
BCR P11274 5/20 0.51
LCK P06239 2/20 0.49
HCK P08631 2/20 0.48
BRAF P15056 2/20 0.48
EGFR P00533 1/20 0.48
FYN P06241 1/20 0.48
YES1 P07947 1/20 0.48
LYN P07948 1/20 0.48
SRC P12931 1/20 0.48
PDGFRA P16234 1/20 0.48
FRK P42685 1/20 0.48
SIK1 P57059 1/20 0.47
SIK2 Q9H0K1 1/20 0.47
SIK3 Q9Y2K2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13878754 0.93 CSF1R (0.53) CSF1RKDM4EPOLBRECQLMAPT
SCHEMBL13878725 0.91 CSF1R (0.63) CSF1RKDM4EPOLBRECQLMAPT
SCHEMBL13878752 0.89 CSF1R (0.57) CSF1RKDM4EPOLBRECQLMAPT
SCHEMBL1704685 0.86 RAF1 (0.54) CSF1RABL1BCRLCKHCK
SCHEMBL13878806 0.85 CSF1R (0.61) CSF1RKDM4EPOLBRECQLMAPT
SCHEMBL13878750 0.85 ABL1 (0.56) CSF1RKDM4EPOLBRECQLMAPT
SCHEMBL1704030 0.85 LCK (0.59) CSF1RABL1LCKHCKBRAF
SCHEMBL13878753 0.85 CSF1R (0.56) CSF1RKDM4EPOLBRECQLMAPT
SCHEMBL13878727 0.84 CSF1R (0.59) CSF1RKDM4EPOLBRECQLMAPT
SCHEMBL13878789 0.82 CSF1R (0.63) CSF1RKDM4EPOLBRECQLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105250-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-23 US disclosed
US-20090105250-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105250-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ABL1, BCR, PDGFRB CSF1R 891/4885KDM4E 2668/4885POLB 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.